Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
The properties of the particles that make up a pharmaceutical powder directly affect its behavior, a classic example being that finer particles are usually associated with poor flowability. However, so too do other ‘system’ variables, such as the degree of aeration or consolidation. The analytical toolkit required for the knowledge-led control of formulation properties therefore necessarily extends from particle characterization through to bulk powder testing techniques. Particle characteristics are the levers manipulated to meet performance targets, but bulk powder properties often define some of these targets. Marrying the results from both types of analysis is often the key to efficient progress.
For an industry in which collaborative working is increasingly the norm, turning to external experts for analytical input provides a cost-effective route to the latest instrumentation, robust, precise measurement and reliable data interpretation.
How far have we come in raw material supply management, and what still needs accomplished to ensure the delivery of safe and effective drugs?
Materials science is now helping pharmaceutical companies to standardize and control areas such as drug form and manufacture to deliver new products more quickly and with greater quality.
Learn how a structured 3-step approach can help overcome the challenge of molecular characterization and a limited budget.
How SYLOID FP silica products contribute significantly in mitigating/resolving key challenges such as formulation stability over time and their ability to withstand challenging processing conditions.
The combined adsorption capacity, porosity, particle size, and density of the SYLOID® XDP silicas provide a tool to convert liquid ingredients into free flowing powder.
Grace’s SYLOID® 244 FP silica is highly porous and an excellent solution for converting viscous Simethicone into compressible free flowing powder to make chewable tablets.
SYLOID® FP and XDP silicas excipients are micronized synthetic amorphous silica gels of high purity which are widely formulated into many pharmaceutical products.